Xifaxan 550 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26FB9QF
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,913
Award facts
- Contract value 100% obligated
- $10,913.02 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $10,913.02 to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units) on January 12, 2026, with an ultimate completion date of January 13, 2026. This non-set-aside contract was competitively awarded and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $1 billion prime vendor agreement valued through December 2026 that serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide.
AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc. (doing business as AmerisourceBergen), is a major pharmaceutical distributor and critical federal vendor specializing in supplying brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. The company's extensive federal contract portfolio with DLA and the Defense Health Agency demonstrates its capability to meet competitive procurement requirements and efficiently fulfill essential pharmaceutical needs for military treatment facilities, veterans' healthcare programs, and other federal medical institutions. The parent organization, Cencora, Inc., holds the primary $1 billion IDC with DLA Troop Support Medical extending through December 2031.
Quick answers
Who was awarded contract SPE2DR26FB9QF?
SPE2DR26FB9QF was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 12, 2026.
How much is contract SPE2DR26FB9QF worth?
The government has obligated $10,913 on SPE2DR26FB9QF.
Is contract SPE2DR26FB9QF an order under another contract?
Yes. SPE2DR26FB9QF is a delivery order under SPE2DR25D2212, an indefinite delivery contract.
Was contract SPE2DR26FB9QF competed?
The extent of competition for SPE2DR26FB9QF was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award